Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice

Three vaccines developed for protection against IA/IB subtypes of Venezuelan equine encephalitis (VEE) virus were evaluated in mice for the ability to protect against systemic and mucosal challenges with a virulent virus of the IE subtype. The vaccines were the formaldehyde-inactivated C-84 and live...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2001-11, Vol.20 (3), p.616-622
Main Authors: Hart, Mary Kate, Lind, Cathleen, Bakken, Russell, Robertson, Michelle, Tammariello, Ralph, Ludwig, George V
Format: Article
Language:English
Subjects:
Animals
Antibodies, Viral - blood
Bacteriology
Biological and medical sciences
Cross-protection
Encephalitis Virus, Venezuelan Equine - classification
Encephalitis Virus, Venezuelan Equine - immunology
Female
Fundamental and applied biological sciences. Psychology
Immunity
Mice
Mice, Inbred BALB C
Microbiology
Time Factors
Vaccination
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Venezuelan equine encephalitis (VEE) virus
Venezuelan equine encephalitis virus
Viral Vaccines - immunology
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three vaccines developed for protection against IA/IB subtypes of Venezuelan equine encephalitis (VEE) virus were evaluated in mice for the ability to protect against systemic and mucosal challenges with a virulent virus of the IE subtype. The vaccines were the formaldehyde-inactivated C-84 and live attenuated TC-83 vaccines currently administered to people under investigational new drug (IND) status, and a new live attenuated vaccine candidate, V3526. V3526 was superior for inducing protection to VEE IA/IB within a week of vaccination, and protection persisted for at least a year. All three vaccines induced long-term clinical protection against peripheral or mucosal challenge with IE virus, with the mucosal immunity induced by attenuated vaccines lasting longer than that induced by the inactivated vaccine. These data show that the molecularly cloned V3526 vaccine induces equivalent or improved immunity to homologous and heterologous VEE viruses than the existing vaccines.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(01)00337-1